

Mony J De Leon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8256172/publications.pdf>

Version: 2024-02-01

182
papers

25,595
citations

9756

73
h-index

6979

154
g-index

221
all docs

221
docs citations

221
times ranked

24763
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
2	Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome. <i>Acta Neuropathologica Communications</i> , 2022, 10, 2.	2.4	12
3	Association Between Systemic Amyloidosis and Intracranial Hemorrhage. <i>Stroke</i> , 2022, 53, STROKEAHA121038451.	1.0	4
4	Brain oxygen extraction and neural tissue susceptibility are associated with cognitive impairment in older individuals. <i>Journal of Neuroimaging</i> , 2022, 32, 697-709.	1.0	5
5	Decreased CSF clearance and increased brain amyloid in Alzheimer's disease. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 21.	2.4	41
6	Quantitative Water Permeability Mapping of Blood-Brain-Barrier Dysfunction in Aging. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 867452.	1.7	14
7	Statistical Parametric Mapping in Amyloid Positron Emission Tomography. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 849932.	1.7	4
8	Obstructive Sleep Apnea and Hypertension with Longitudinal Amyloid- β Burden and Cognitive Changes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 632-636.	2.5	7
9	Association between lower body temperature and increased tau pathology in cognitively normal older adults. <i>Neurobiology of Disease</i> , 2022, 171, 105748.	2.1	3
10	Quantifying cerebrospinal fluid dynamics: A review of human neuroimaging contributions to CSF physiology and neurodegenerative disease. <i>Neurobiology of Disease</i> , 2022, 170, 105776.	2.1	18
11	Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression. <i>Alzheimer's and Dementia</i> , 2021, 17, 226-245.	0.4	23
12	Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 21-44.	0.9	8
13	Periodontal dysbiosis associates with reduced CSF A β 42 in cognitively normal elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12172.	1.2	18
14	Cognitive dysfunction in young subjects with periodontal disease. <i>Neurological Sciences</i> , 2021, 42, 4511-4519.	0.9	9
15	Betahydroxybutyrate Consumption in Autopsy Brain Tissue from Alzheimer's Disease Subjects. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 135-141.	1.2	2
16	Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. <i>Scientific Reports</i> , 2021, 11, 10867.	1.6	79
17	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
18	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. <i>Contemporary Clinical Trials</i> , 2021, 107, 106488.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Obesity and Race May Explain Differential Burden of White Matter Hyperintensity Load. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1563-1571.	1.3	6
20	Diffusion tensor-based analysis of white matter in the healthy aging canine brain. <i>Neurobiology of Aging</i> , 2021, 105, 129-136.	1.5	7
21	Abstract MP13: Evaluation Of The Effect Of Low Grade Inflammation And Hypertension On The Development Of White Matter Lesions. <i>Hypertension</i> , 2021, 78, .	1.3	0
22	Heuristic scoring method utilizing FDG-PET statistical parametric mapping in the evaluation of suspected Alzheimer disease and frontotemporal lobar degeneration. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 313-326.	1.0	1
23	The Brain-Nose Interface: A Potential Cerebrospinal Fluid Clearance Site in Humans. <i>Frontiers in Physiology</i> , 2021, 12, 769948.	1.3	15
24	Interactive Associations of Neuropsychiatry Inventory-Questionnaire Assessed Sleep Disturbance and Vascular Risk on Alzheimer's Disease Stage Progression in Clinically Normal Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 763264.	1.7	6
25	Effects of blood pressure on white matter lesions and brain volumes in hypertensive and normotensive subjects.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053826.	0.4	0
26	Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research. <i>Sleep Medicine Reviews</i> , 2020, 50, 101250.	3.8	182
27	Clearance of interstitial fluid (ISF) and CSF (CLIC) group part of Vascular Professional Interest Area (PIA). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12053.	1.2	53
28	The LUCINDA trial: Leuprolide + cholinesterase inhibition to reduce neurologic decline in Alzheimer's. <i>Alzheimer's and Dementia</i> , 2020, 16, e038780.	0.4	0
29	Periodontal disease as a possible cause for Alzheimer's disease. <i>Periodontology 2000</i> , 2020, 83, 242-271.	6.3	76
30	Sex-driven modifiers of Alzheimer risk. <i>Neurology</i> , 2020, 95, e166-e178.	1.5	87
31	Synthesis of [¹¹ C]Butanol via a facile solid phase extraction protocol. <i>Applied Radiation and Isotopes</i> , 2020, 159, 109078.	0.7	2
32	Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 483-492.	1.2	86
33	Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment). <i>Journal of Alzheimer's Disease</i> , 2019, 67, 685-705.	1.2	9
34	Precisely-Measured Hydration Status Correlates with Hippocampal Volume in Healthy Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 653-654.	0.6	4
35	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. <i>Molecular Neurodegeneration</i> , 2019, 14, 10.	4.4	61
36	ICAD104: LONGITUDINAL CHANGES OF STRUCTURAL AND FUNCTIONAL CONNECTIVITY AND CORRELATIONS WITH GENETICS AND NEUROCOGNITIVE METRICS. <i>Alzheimer's and Dementia</i> , 2019, 15, P90.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Different Relationship Between Systolic Blood Pressure and Cerebral Perfusion in Subjects With and Without Hypertension. Hypertension, 2019, 73, 197-205.	1.3	39
38	Reply: Cerebrospinal Fluid, Hyposmia, and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis. Journal of Nuclear Medicine, 2018, 59, 718.2-719.	2.8	1
39	Basal forebrain septal nuclei are enlarged in healthy subjects prior to the development of Alzheimer's disease. Neurobiology of Aging, 2018, 65, 201-205.	1.5	25
40	Challenges associated with biomarker-based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	1.2	37
41	Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology, 2018, 90, e1789-e1798.	1.5	186
42	Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link. EBioMedicine, 2018, 28, 21-30.	2.7	250
43	Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1596-1604.	3.3	15
44	Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area. BMJ Open, 2018, 8, e019362.	0.8	58
45	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
46	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
47	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
48	Obstructive Sleep Apnea Severity Affects Amyloid Burden in Cognitively Normal Elderly. A Longitudinal Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 933-943.	2.5	174
49	ICP-002: OBSTRUCTIVE SLEEP APNEA, BRAIN BETA-AMYLOID MEASURES AND TIME-TO-PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P15.	0.4	0
50	ICP-014: SLEEP DISORDERED BREATHING AND BRAIN BETA-AMYLOID BOTH PREDICT TIME-TO-PROGRESSION FROM NORMAL COGNITION TO MILD COGNITIVE IMPAIRMENT WITH BRAIN BETA-AMYLOID MODIFYING THE PROGRESSION RISK. Alzheimer's and Dementia, 2018, 14, P130.	0.4	0
51	Military-related risk factors for dementia. Alzheimer's and Dementia, 2018, 14, 1651-1662.	0.4	18
52	P2-074: IMPAIRED CSF CLEARANCE AND BRAIN AMYLOID IN ALZHEIMER'S DISEASE: A MULTI-TRACER PET STUDY. Alzheimer's and Dementia, 2018, 14, P695.	0.4	0
53	Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open, 2018, 8, e023664.	0.8	30
54	Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. PLoS ONE, 2018, 13, e0207885.	1.1	123

#	ARTICLE	IF	CITATIONS
55	P2â€128: DECREASED TOTAL SLEEP TIME IN AMYLOID NEGATIVE APOE4 CARRIERS: A NEW CLINICAL ENDOPHENOTYPE?. Alzheimer's and Dementia, 2018, 14, P717.	0.4	0
56	P2â€230: CHALLENGES ASSOCIATED WITH BIOMARKERâ€BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P756.	0.4	0
57	Therapeutic potential for peripheral clearance of misfolded brain proteins. Nature Reviews Neurology, 2018, 14, 637-638.	4.9	8
58	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	4.9	140
59	Carbonic anhydrase inhibition selectively prevents amyloid Î² neurovascular mitochondrial toxicity. Aging Cell, 2018, 17, e12787.	3.0	64
60	The nonlinear relationship between cerebrospinal fluid AÎ²42 and tau in preclinical Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0191240.	1.1	41
61	Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or Î²-Amyloidosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 439-457.	0.9	14
62	Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. Journal of Nuclear Medicine, 2017, 58, 1471-1476.	2.8	161
63	Sex differences in Alzheimer risk. Neurology, 2017, 89, 1382-1390.	1.5	177
64	Perimenopause and emergence of an Alzheimerâ€™s bioenergetic phenotype in brain and periphery. PLoS ONE, 2017, 12, e0185926.	1.1	95
65	Relationship between Clinical Parameters and Brain Structure in Sporadic Amyotrophic Lateral Sclerosis Patients According to Onset Type: A Voxel-Based Morphometric Study. PLoS ONE, 2017, 12, e0168424.	1.1	21
66	Brain Atrophy of Secondary REM-Sleep Behavior Disorder in Neurodegenerative Disease. Journal of Alzheimer's Disease, 2016, 52, 1101-1109.	1.2	29
67	The Alzheimer's Imaging Consortium: Celebrating 20Âyears of creativity and progress. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 3-4.	1.2	0
68	Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 95-104.	1.2	24
69	Transient and chronic seizureâ€induced inflammation in human focal epilepsy. Epilepsia, 2016, 57, e191-4.	2.6	52
70	Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. Sleep, 2016, 39, 1253-1260.	0.6	44
71	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid AÎ²42 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	0.6	140
72	Periodontal disease's contribution to Alzheimer's disease progression inÂDown syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 49-57.	1.2	32

#	ARTICLE	IF	CITATIONS
73	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 93-100.	1.2	35
74	Letter to the editor regarding: Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 385-386.	1.2	8
75	<i>APOE</i>-by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015, 6, 26663-26674.	0.8	92
76	Cortical Laminar Binding of PET Amyloid and Tau Tracers in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 270-273.	2.8	22
77	Comparison of the Brain Volume in Essential Tremor and Parkinson's Disease Tremor Using an Automated Segmentation Method. <i>European Neurology</i> , 2015, 73, 303-309.	0.6	23
78	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	3.7	109
79	Clearance systems in the brain—implications for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2015, 11, 457-470.	4.9	1,127
80	Sleep-disordered breathing advances cognitive decline in the elderly. <i>Neurology</i> , 2015, 84, 1964-1971.	1.5	313
81	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
82	Periodontal disease associates with higher brain amyloid load in normal elderly. <i>Neurobiology of Aging</i> , 2015, 36, 627-633.	1.5	198
83	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 58-69.	0.4	352
84	Single Photon Emission Computerized Tomography and Neuropsychological Tests That Predict a Good Response to Donepezil Therapy for Alzheimer's Disease. <i>Dementia and Neurocognitive Disorders</i> , 2015, 14, 106.	0.4	1
85	Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study. <i>BMJ Open</i> , 2014, 4, e004850-e004850.	0.8	66
86	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
87	Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. <i>Neurobiology of Aging</i> , 2014, 35, 64-71.	1.5	66
88	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.4	249
89	The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. <i>Neurobiology of Aging</i> , 2014, 35, 1318-1324.	1.5	109
90	FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease. <i>Advances in Molecular Imaging</i> , 2014, 04, 15-26.	0.3	31

#	ARTICLE	IF	CITATIONS
91	Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's Disease: A Multi-Modality Brain Imaging Study. <i>Advances in Molecular Imaging</i> , 2014, 04, 43-57.	0.3	56
92	Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. <i>Neurobiology of Aging</i> , 2013, 34, 22-34.	1.5	58
93	Inge Grundke-Iqbal, Ph.D. (1937-2012): the Discoverer of the Abnormal Hyperphosphorylation of Tau in Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 49, 430-435.	1.1	3
94	Posterior Cingulate Glucose Metabolism, Hippocampal Glucose Metabolism, and Hippocampal Volume in Cognitively Normal, Late-Middle-Aged Persons at 3 Levels of Genetic Risk for Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 320.	4.5	123
95	Cerebrovascular Reactivity to Carbon Dioxide in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 427-440.	1.2	106
96	Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer's Disease Transgenic Mice Using Magnetic Resonance Microimaging. <i>PLoS ONE</i> , 2013, 8, e57097.	1.1	91
97	Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. <i>Neurobiology of Aging</i> , 2012, 33, 1215-1227.	1.5	61
98	Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 624.e1-624.e9.	1.5	12
99	Abnormal Intracellular Accumulation and Extracellular A β Deposition in Idiopathic and Dup15q11.2-q13 Autism Spectrum Disorders. <i>PLoS ONE</i> , 2012, 7, e35414.	1.1	48
100	Detection of amyloid plaques targeted by USPIO-A β 1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. <i>NeuroImage</i> , 2011, 55, 1600-1609.	2.1	126
101	Reduced Mitochondria Cytochrome Oxidase Activity in Adult Children of Mothers with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 483-490.	1.2	85
102	Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders. <i>Neurobiology of Aging</i> , 2011, 32, 2131-2141.	1.5	43
103	Structural brain changes in normal individuals with a maternal history of Alzheimer's. <i>Neurobiology of Aging</i> , 2011, 32, 2325.e17-2325.e26.	1.5	47
104	Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 36-50.	0.9	69
105	GREATER RISK OF ALZHEIMER'S DISEASE IN OLDER ADULTS WITH INSOMNIA. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 559-562.	1.3	139
106	Framingham Cardiovascular Risk Profile Correlates with Impaired Hippocampal and Cortical Vasoreactivity to Hypercapnia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 671-679.	2.4	59
107	Hippocampal blood flow in normal aging measured with arterial spin labeling at 3T. <i>Magnetic Resonance in Medicine</i> , 2011, 65, 128-137.	1.9	26
108	Midbrain Atrophy in Vascular Parkinsonism. <i>European Neurology</i> , 2011, 65, 296-301.	0.6	21

#	ARTICLE	IF	CITATIONS
109	Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging. Journal of Alzheimer's Disease, 2010, 20, 843-854.	1.2	230
110	The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathologica, 2010, 119, 755-770.	3.9	485
111	Increased fibrillar amyloid- β^2 burden in normal individuals with a family history of late-onset Alzheimer's. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5949-5954.	3.3	125
112	Evaluation of Early Dementia (Mild Cognitive Impairment). PET Clinics, 2010, 5, 15-31.	1.5	4
113	Oxidative Stress and Amyloid-Beta Pathology in Normal Individuals with A Maternal History of Alzheimer's. Biological Psychiatry, 2010, 68, 913-921.	0.7	44
114	Twelve-month metabolic declines in probable Alzheimer's disease and amnesic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. NeuroImage, 2010, 51, 654-664.	2.1	145
115	Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiology of Aging, 2010, 31, 1077-1088.	1.5	261
116	Does mild cognitive impairment increase the risk of developing postoperative cognitive dysfunction?. American Journal of Surgery, 2010, 199, 782-788.	0.9	70
117	Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.		

#	ARTICLE	IF	CITATIONS
127	Hypometabolism and Altered Cerebrospinal Fluid Markers in Normal Apolipoprotein E E4 Carriers with Subjective Memory Complaints. <i>Biological Psychiatry</i> , 2008, 63, 609-618.	0.7	213
128	Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. <i>Biological Psychiatry</i> , 2008, 64, 871-879.	0.7	329
129	Hippocampal hypometabolism predicts cognitive decline from normal aging. <i>Neurobiology of Aging</i> , 2008, 29, 676-692.	1.5	292
130	A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. <i>Neurobiology of Aging</i> , 2008, 29, 836-847.	1.5	60
131	Memantine decreases hippocampal glutamate levels: A magnetic resonance spectroscopy study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1005-1012.	2.5	25
132	Mild cognitive impairment (MCI): a historical perspective. <i>International Psychogeriatrics</i> , 2008, 20, 18-31.	0.6	93
133	Multicenter Standardized ¹⁸ F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias. <i>Journal of Nuclear Medicine</i> , 2008, 49, 390-398.	2.8	637
134	Anteroposterior Hippocampal Metabolic Heterogeneity: Three-dimensional Multivoxel Proton ¹ H MR Spectroscopic Imaging Initial Findings. <i>Radiology</i> , 2008, 249, 242-250.	3.6	20
135	Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related cognitive decline. <i>Neuropsychology</i> , 2008, 22, 469-484.	1.0	74
136	Alzheimer's Disease and Peripheral Infections: The Possible Contribution from Periodontal Infections, Model and Hypothesis. <i>Journal of Alzheimer's Disease</i> , 2008, 13, 437-449.	1.2	137
137	Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19067-19072.	3.3	218
138	Subjective Memory Complaints: Presence, Severity and Future Outcome in Normal Older Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 177-184.	0.7	148
139	¹⁸ F-FDG PET Database of Longitudinally Confirmed Healthy Elderly Individuals Improves Detection of Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1129-1134.	2.8	68
140	Seeing what Alzheimer saw. <i>Nature Medicine</i> , 2007, 13, 129-131.	15.2	11
141	Early detection of Alzheimer's disease using neuroimaging. <i>Experimental Gerontology</i> , 2007, 42, 129-138.	1.2	140
142	Mild cognitive impairment. <i>Lancet</i> , The, 2006, 367, 1262-1270.	6.3	2,401
143	Biomarkers for the early diagnosis of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2006, 5, 198-199.	4.9	24
144	Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1778-86.	2.8	195

#	ARTICLE	IF	CITATIONS
145	Absence of hippocampal volume differences in survivors of the Nazi Holocaust with and without posttraumatic stress disorder. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 53-64.	0.9	89
146	Subjective memory complaints in aging are associated with elevated cortisol levels. <i>Neurobiology of Aging</i> , 2005, 26, 1357-1363.	1.5	57
147	Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 831-849.	1.4	41
148	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, 977-989.	1.5	90
149	Biological markers for therapeutic trials in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2003, 24, 521-536.	1.5	249
150	Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2019-2022.	3.3	295
151	Regional Brain Atrophy Rate Predicts Future Cognitive Decline: 6-year Longitudinal MR Imaging Study of Normal Aging. <i>Radiology</i> , 2003, 229, 691-696.	3.6	253
152	Hippocampal Atrophy Disrupts Transfer Generalization in Nondemented Elderly. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 82-90.	1.2	61
153	Basal Hypothalamo-Pituitary-Adrenal Axis Activity and Corticotropin Feedback in Young and Older Men: Relationships to Magnetic Resonance Imaging-Derived Hippocampus and Cingulate Gyrus Volumes. <i>Neuroendocrinology</i> , 2002, 75, 241-249.	1.2	84
154	Salivary cortisol day profiles in elderly with mild cognitive impairment. <i>Psychoneuroendocrinology</i> , 2002, 27, 777-789.	1.3	62
155	Changes in brain functional homogeneity in subjects with Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2002, 114, 39-50.	0.9	41
156	Hippocampal formation glucose metabolism and volume losses in MCI and AD. <i>Neurobiology of Aging</i> , 2001, 22, 529-539.	1.5	511
157	Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2001, 107, 61-73.	0.9	119
158	Shift from fibrillar to nonfibrillar A β deposits in the neocortex of subjects with Alzheimer disease. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 49-57.	1.2	12
159	Fibrillar amyloid- β affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration. <i>Acta Neuropathologica</i> , 2001, 101, 585-590.	3.9	4
160	Positron Emission Tomography in Evaluation of Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2120.	3.8	803
161	Cerebellar atrophy in Alzheimer's disease's clinicopathological correlations. <i>Brain Research</i> , 1999, 818, 41-50.	1.1	111
162	Corticosteroids, the Aging Brain and Cognition. <i>Trends in Endocrinology and Metabolism</i> , 1999, 10, 92-96.	3.1	93

#	ARTICLE	IF	CITATIONS
163	MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. <i>Psychiatry Research - Neuroimaging</i> , 1999, 90, 113-123.	0.9	117
164	Cortisol levels during human aging predict hippocampal atrophy and memory deficits. <i>Nature Neuroscience</i> , 1998, 1, 69-73.	7.1	1,425
165	Duration of neurofibrillary changes in the hippocampal pyramidal neurons. <i>Brain Research</i> , 1998, 799, 156-158.	1.1	40
166	Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. <i>Brain Research</i> , 1998, 805, 267-269.	1.1	108
167	Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 1998, 89, 742-747.	0.9	47
168	Relationships between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 414-420.	0.9	181
169	Contribution of Structural Neuroimaging to the Early Diagnosis of Alzheimer's Disease. <i>International Psychogeriatrics</i> , 1997, 9, 183-190.	0.6	82
170	<title>Spatial distribution of residual error in 3D image coregistration: an experimental study</title>. , 1997, , .		0
171	Mortality and Temporal Course of Probable Alzheimer's Disease: A 5-Year Prospective Study. <i>International Psychogeriatrics</i> , 1996, 8, 291-311.	0.6	75
172	Age-related changes in brain: I. Magnetic resonance imaging measures of temporal lobe volumes in normal subjects. <i>Psychiatric Quarterly</i> , 1995, 66, 343-355.	1.1	38
173	Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. <i>Psychiatric Quarterly</i> , 1995, 66, 357-370.	1.1	72
174	Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. <i>Drug Development Research</i> , 1988, 15, 101-114.	1.4	140
175	Positron emission tomography studies of normal aging: A replication of PET III and 18-FDG using PET VI and 11-CDG. <i>Neurobiology of Aging</i> , 1987, 8, 319-323.	1.5	81
176	Periventricular lucencies in the CT scans of aged and demented patients. <i>Biological Psychiatry</i> , 1986, 21, 960-962.	0.7	31
177	Reduced incidence of left-handedness in clinically diagnosed dementia of the Alzheimer type. <i>Neurobiology of Aging</i> , 1986, 7, 161-164.	1.5	21
178	Structural and functional neuroimaging in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1986, 7, 396-398.	1.5	0
179	Positron Emission Tomography and Computed Tomography Assessments of the Aging Human Brain. <i>Journal of Computer Assisted Tomography</i> , 1984, 8, 88-94.	0.5	93
180	Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1983, 3, 391-394.	2.4	188

#	ARTICLE	IF	CITATIONS
181	Central amine metabolism in Alzheimer's disease: In vivo relationship to cognitive deficit. <i>Neurobiology of Aging</i> , 1981, 2, 57-60.	1.5	65
182	Positron Emission Tomography in the Study of Aging and Senile Dementia. <i>Neurobiology of Aging</i> , 1980, 1, 127-131.	1.5	176